Robert Davis, Merck CEO
November 1, 2021 07:07 AM EDT
Deals

Mer­ck de­lays $11.5B Ac­celeron buy­out to give an­titrust watch­dog 'ad­di­tion­al time for re­view'

Nicole DeFeudis

Editor

Mer­ck’s $11.5 bil­lion Ac­celeron Phar­ma buy­out may not hap­pen quite as soon as the Ke­nil­worth, NJ-based phar­ma com­pa­ny had hoped.

On Fri­day, Mer­ck

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times